Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Aims to Enhance Opioid Analgesic Effects with Specific Cannabis Strain

Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Aims to Enhance Opioid Analgesic Effects with Specific Cannabis Strain
Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Aims to Enhance Opioid Analgesic Effects with Specific Cannabis Strain

  • Unique scientific approach lends more credibility and increases consumer confidence
  • Huge potential for cannabis to replace opioids as analgesics
  • Strategic partnerships position Veritas strongly in the medical cannabis industry

On September 13, 2017, Cannevert Therapeutics Ltd. (“CTL”), the research arm of Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP), filed a provisional patent for the use of a specific strain of cannabis to enhance the actions of opioid analgesics. Opioid analgesics are traditionally prescribed for relief of acute and chronic pain. However, over-prescription or prolonged use can lead to addiction. Recreational users of opioids commonly run the risk of fatal overdose, with more than 33,000 deaths from opioid overdose reported in 2015, according to the U.S. Centers for Disease Control and Prevention. Cannabinoids found in cannabis provide similar pain relief to opioids, but without the side effects and fatality risk. There is evidence that cannabinoids and opioids can work in synergy to moderate pain. As restrictions on the use of cannabis are eased, there is tremendous potential for cannabis to provide a safe alternative to opioids as an analgesic.

Veritas Pharma employs a scientific approach to support medical cannabis claims and is intent on developing and commercializing the most effective strains of cannabis for medical use. The company is concerned that, with the rapid growth of the medical cannabis industry, product quality is inconsistent and scientific proof of effectiveness is lacking. By forming strategic alliances and partnerships within the industry, the company intends to address this issue. Its approach to research and development is aimed firstly at chemically profiling the various cultivars of cannabis. As a second step, each cultivar is pharmacologically profiled to identify strains for specific diseases before clinical trials are undertaken to establish each cultivar’s utility and efficacy. By using this approach, Veritas will provide physicians and patients the scientific evidence necessary to enable them to use its products with confidence.

Read the full article

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer